Skip to content
DraconiticResearch
Search Sources API
190,860 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NCMedicine

Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis : A real-world disproportionality and machine learning analysis

  • Junmo Moon1
  • Chaemin Lee1
  • Seoyeong Lee1
  • Meehoh Kim1
  • Xuerong Wen2
  • Francesco Branda3
  • Jeongseon Oh1
  • Yejun Son1
  • Kyeongmin Lee1
  • Taelim Choi1
  • Dong Keon Yon1
  1. 1Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea
  2. 2Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston, RI
  3. 3Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, Rome, Italy
Read full textPDFCite

Related

  1. Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.
    Christian Ciolfi, Bernd Raffeiner, Margherita Zen +3
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  2. Sustained pain improvement and IL-12-related biomarker changes in rheumatoid arthritis patients initiating baricitinib or TNF inhibitor therapy
    Christine Behrendt, Khetam Ghannam, Monika Brunner-Weinzierl +4
    EULAR Rheumatology OpenPeer-reviewedCC BY 4.0Full textGeneral medicinePMCEurope PMC
  3. Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients.
    Irini Flouri, Antonios Bertsias, Konstantina Zoupidou +12
    Rheumatology internationalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Recurrent hypofibrinogenemia after reduced-dose tocilizumab rechallenge in rheumatoid arthritis: a case report
    Yanbiao Li, Yuhe Yan, Hua Zhou +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCPMCEurope PMC
  5. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: An External Validation of the BRASS Registry
    Misti L. Paudel, Katherine Liao, Jon T. Giles +8
    Arthritis care & researchPeer-reviewedLicence not statedFull textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{moon2026cardiovascular,
  title = {{Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis : A real-world disproportionality and machine learning analysis}},
  author = {Junmo Moon and Chaemin Lee and Seoyeong Lee and Meehoh Kim and Xuerong Wen and Francesco Branda and Jeongseon Oh and Yejun Son and Kyeongmin Lee and Taelim Choi and Dong Keon Yon},
  journal = {Medicine},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13706441},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis : A real-world disproportionality and machine learning analysis
AU  - Junmo Moon
AU  - Chaemin Lee
AU  - Seoyeong Lee
AU  - Meehoh Kim
AU  - Xuerong Wen
AU  - Francesco Branda
AU  - Jeongseon Oh
AU  - Yejun Son
AU  - Kyeongmin Lee
AU  - Taelim Choi
AU  - Dong Keon Yon
PY  - 2026
DA  - 2026/10/23
JO  - Medicine
UR  - https://europepmc.org/article/PMC/PMC13706441
SN  - 0304-5412
SN  - 1536-5964
ER  -